Key facts
- China aims to achieve global leadership in drug innovation by 2030.
- The country targets holding 25% of the world's first-in-class drugs by 2030.
- A five-year plan seeks to grow China's innovative-drug sector by over 20% annually through 2030.
- The plan aims for at least five Chinese drugs to achieve global annual sales exceeding $1 billion.
- Focus areas include gene editing, cell therapies, and AI-designed drugs.
China is setting ambitious targets to become a global leader in biopharmaceutical innovation, aiming to account for 25% of the world's first-in-class drugs by 2030. This strategic push is underpinned by supportive government policies and a significant increase in investment dedicated to research and development within the pharmaceutical sector.
The nation's focus is particularly directed towards therapeutic areas such as oncology and the treatment of rare diseases. The strategy encompasses fostering homegrown innovation while simultaneously working to attract international scientific talent to bolster the capabilities of its pharmaceutical industry. This initiative signals a shift towards higher-value drug development and away from generic manufacturing, positioning China as a key player in cutting-edge medical advancements.
